Regulatory Novartis receives European Commission approval for Itvisma for spinal muscular atrophy PharmaTimesEC backs first gene replacement therapy for broad sma populationRare DiseaseRead full story pharminent July 2, 2026 (Last updated: July 3, 2026) PharmaTimes EC backs first gene replacement therapy for broad sma population Rare Disease Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: AZ forges ever-closer ties with China’s CSPC PharmaNext: Biogen Bets on Tau at AAIC: Diranersen Phase 2 CELIA Data Related Stories Regulatory Lilly plans Q1 2027 filing for obesity triple retatrutide pharminent July 23, 2026 Regulatory GSK’s $10.6B Nuvalent bet pays off early as FDA approves lung cancer drug pharminent July 23, 2026 Regulatory Celcuity gains FDA approval for closely watched breast cancer drug pharminent July 15, 2026
